Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No need to strain your brain doing math
ihub lists the 'Dollar Volume' on its BIEL 'Quote' Page.
Interesting how your math errors are always in the direction of minimizing BIEL.
Ya Really Need to get that Calculator Replaced or people will think you are making false posts on purpose
<<<<<<<<<< $15K was traded and flipped today >>>>>>>>>>
Per ihub 'Dollar Volume' was $19,439 today.
Buys = 30.2 million shares
Sells = 806k shares
Neutral = 1.7 million shares
MMs had to Short 30.2 million shares of a 32.8 million share total to keep BIEL from moving to a 7 Ask Price.
Date ... Symbol . Short Vol ... Total Vol
20230109|BIEL|30272596|0|32864633
Blah, Blah, Blah as we Hit 29.6 million in Volume
Buys = 27 million shares
Sells = 800k shares
Neutral = 1.8 million Shares
5 Bid Size = 31.4 million shares
6 Ask Size = 5.9 million shares
Still looks very good to me, 99.4% Buys
17.7 million shares Traded after 3 hours.
Buys = 17.6 million shares
Sells = 106k shares
5 bid Size = 21 million shares
6 Ask size = 6 million shares
11.6 Million Share Buy at 6 at the Open
LOL, MMs Paint it Down to .00055 ten seconds later with 1,000 share Trade.
Soooo, when you buy 1,000 of these devices, to get the $13 price and go to sell them for $25, they say "7 Day Trial Device" on the carton. How is anyone going to believe that this sealed carton contains anything other than a 7 Day Trial device?
Using, "the guy who sold them to me said they were 360 hours" is not going to cut it with 99% of potential customers.
Says 7 Day Trial Device Right on the Carton
Which is more likely to be correct:
Printing on the box or a description written up in an ad?
That is a 7 Day Trial Device (168 hour) not the 720 hour ActiPatch
Good luck getting $25 for 7 days when 30 day ActiPatch available on ebay for $29 or 250 hour KT Wave for $19.
This is a CICD promotion. They are the ActiPatch manufacturer. I doubt they would be able to ship ActiPatch to the US unless BIEL sanctioned the purchase.
Time for a new calculator
<<<<<<<< one or two people spent $4000.00 total today >>>>>>>>>>
8.6 million shares @ .0006 = $5,160
Nice try.
LMAO, Buyers Totally Dominated BIEL Today
The only reason BIEL did not close at 6, where 99% of the transactions occurred, was because an MM stepped in on the last Buy of the day and sold for a .000575 price instead of the 6 Ask.
How do we know it was an MM? Retail Investors are limited to 4 digits to the right of the decimal point when placing an order. So the last trade of the day, a 100,570 share Buy order, was placed at 6 and it was Painted Down to .000575 .
8.6 million Buys
4,000 Sells
6 Hours of Trading and Sellers are MIA, 99.8% Buys Today
19 million shares on the Bid at 5 but the MMs not selling at 5.
Buys = 8.3 million shares
Sells = 4,000 shares
"CITE THE JOURNAL ARTICLE." 'Pain Research and Management'
A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel
OTC Neuromodulation Therapy
Received 25 June 2019; Accepted 7 September 2019; Published 30 September 2019
"Results. Seven days after initial treatment, the average pain was reduced to 2.9, a 65% pain reduction for the study subjects. At the 6-month measurement, the average pain was 3.3, a 60% pain reduction from baseline."
"A decline in treatment effectiveness is commonly associated
with long-term use of pharmacological treatments, for example, with NSAIDS [26] and opioids, owing to tolerance [27].The goal of this prospective study is to assess the durability of treatment effectiveness for the PSWT medical device over a 6-month period".
Table 3: Analgesic medications used by the study sample.
Analgesics Fraction of users (%)
NSAIDS (e.g., ibuprofen) 43
Paracetamol 61
Weak opioids (e.g., codeine) 25
Strong opioids (e.g., hydrocodone) 11
Tramadol or equivalent 8
Pregabalin (e.g., Lyrica) 8
Amitriptyline 17
Topical opioid (e.g., morphine) 8
Topical NSAIDS (e.g., Voltarol) 21
Gabapentin 2
Other 4
No analgesics 5
"Pain Research and Management is a peer-reviewed, open access journal which publishes original research articles and review articles involving laboratory, including neuroimaging and neurophysiology, and clinical findings in the field of pain research. The journal also looks into the prevention, treatment and management of pain. The journal aims to increase the current knowledge about the pain mechanisms and encouraging the development of effective and safety treatments for pain. "
https://downloads.hindawi.com/journals/prm/2019/3154194.pdf
Your concerns have been addressed ......
5 million share Buy @ 6 at 11:59
NASA Conclusions:
5.3 Conclusions
The information obtained in the execution of this review effort leads to 2 recommendations for forward work:
1. Tie into DoD and NIH research funding efforts to improve pain treatment: the NIH has a
federal partners workgroup for their HEAL Initiative that could conceivably be joined by
NASA, and the DoD CPMRP’s initial solicitation only recently completed so that program is
young and potentially synergies could be identified with NASA.
2. Obtain an ActiPatch device for evaluation and determine whether it could be beneficial and adapted to spaceflight use. (page 16)
https://ntrs.nasa.gov/api/citations/20205008893/downloads/2020ICA_Mullenax_report_24Sep20.pdf
NASA, working to improve life in Space
BIEL, working to Improve Life on Earth, and soon Space as well!
It is not the possibility of an 'Astronaut Market' it is the Publicity of being able to say ......
NASA Astronauts use ActiPatch for Pain Relief in Space
KT Health Pays $6,493 to Renew FDA Registration for ActiPatch
Establishment Name .... Registration Number ..... Current Registration Yr
KT Health LLC ................... 3007282994 ..................... 2023
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm (search Product code 'PQY')
Surgical Appliance Industries Pays $6,493 to Renew FDA Registration for ActiPatch
Establishment Name ................................... Registration Number ..... Current Registration Yr
Surgical Appliance Industries ................................1511629 ......................... 2023
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm (search Product code 'PQY')
Airway Surgical Appliances Pays $6,493 to Renew FDA Registration for ActiPatch
Establishment Name ................................... Registration Number ..... Current Registration Yr
AIRWAY SURGICAL APPLIANCES LTD .............9611956 ............................. 2023
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm (search Product code 'PQY')
NASA Ranks ActiPatch First in order of perceived ability to implement during spaceflight
"The treatment method ranked first in this review was pulsed
shortwave therapy (PSWT), a low-power RF (MHz range)
transmitter operated adjacent to biological tissue at maximum
output (saturation) to modulate peripheral nerve activity.
ActiPatch is a very small wearable PSWT device that is FDA
approved for “adjunctive treatment of musculoskeletal pain”
[Anwar-Deen 2020]. It is low cost, low power, and boasts 97%
efficacy in reducing pain (85% over a 6-month period) [Staelin
2019]. The device can be secured to the body by physio tape and
the area causing pain is bounded by the device’s ring. The device
can be turned on and off, and the non-rechargeable battery is capable of 720 hours of operation (one month continuous use). ActiPatch is sold OTC in local pharmacies for ~$30 [ActiPatch 2020]" page 15
https://ntrs.nasa.gov/api/citations/20205008893/downloads/2020ICA_Mullenax_report_24Sep20.pdf
NASA likes the Idea of Electromagnetic Pain Relief, Portable, Noninvasive
Electromagnetic Pain Relief/Blocking: Feasibility Assessment
Carol Mullenax, PhD, PE, PMP
KBR, Inc.
2020 Innovation Charge Account Award
JSC Chief Technology Office
September 24, 2020
National Aeronautics and Space Administration
Lyndon B. Johnson Space Center
Houston, Texas 77058
1.0 ABSTRACT/EXECUTIVE SUMMARY
Context/Background: Astronauts use pharmaceuticals during spaceflight to manage acute and
chronic pain, but use of analgesics will have drawbacks for exploration-class missions because
the shelf life of these medications is limited, resupply will be curtailed, astronauts may develop
tolerance and/or addiction to these medications, and side effects can include impairment of
cognitive abilities. Electromagnetic devices have been developed that treat pain terrestrially by
affecting neuromodulation–dubbed “electroceuticals”, these devices have varied mechanisms of
action that either stimulate or suppress neural activity in the central nervous system or peripheral
nerves.
https://ntrs.nasa.gov/api/citations/20205008893/downloads/2020ICA_Mullenax_report_24Sep20.pdf
"data published in a peer-reviewed journal"
Hindawi is a well respected Peer-Reviewed Journal. This is an ActiPatch Study but as most BIEL followers know by now ActiPatch and RecoveryRX are the same device.
Hindawi
Pain Research and Management
A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel
OTC Neuromodulation Therapy
Received 25 June 2019; Accepted 7 September 2019; Published 30 September 2019
"Results. Seven days after initial treatment, the average pain was reduced to 2.9, a 65% pain reduction for the study subjects. At the 6-month measurement, the average pain was 3.3, a 60% pain reduction from baseline."
"A decline in treatment effectiveness is commonly associated
with long-term use of pharmacological treatments, for example, with NSAIDS [26] and opioids, owing to tolerance [27].The goal of this prospective study is to assess the durability of treatment effectiveness for the PSWT medical device over a 6-month period".
Table 3: Analgesic medications used by the study sample.
Analgesics Fraction of users (%)
NSAIDS (e.g., ibuprofen) 43
Paracetamol 61
Weak opioids (e.g., codeine) 25
Strong opioids (e.g., hydrocodone) 11
Tramadol or equivalent 8
Pregabalin (e.g., Lyrica) 8
Amitriptyline 17
Topical opioid (e.g., morphine) 8
Topical NSAIDS (e.g., Voltarol) 21
Gabapentin 2
Other 4
No analgesics 5
https://downloads.hindawi.com/journals/prm/2019/3154194.pdf
Does anyone really think that cash strapped BIEL is spending money hiring a Centers for Medicare/Medicaid Services Medical Biller/Coder without confirming that the 'No Pain' bill will apply to their products?
I would not call the 12/21/2020 shipment to KT "Hype"
16 Pallets
8,543 pounds
3,770 cartons
Nor the 4/25/2021 shipment to KT
20 pallets
11,384 pounds
4,332 cartons
Nor the 6/28/2021 shipment to KT
14 pallets
7,790 pounds
2,848 cartons
IMO, KT priced the Wave too high, $34.99, for 250 hours. This is 14 cents per hour when ActiPatch at $29.99 for 720 hours equals 4.1 cents per hour. BIEL has no control over KT's pricing strategy.
KT dropped the RRP to $29.99 a couple of months ago. This will help but they still need to move closer to the ActiPatch per hour pricing. The price difference between a 250 hour battery and a 720 hour battery in bulk quantities is a few cents.
KT needs the Wave as it is their only FDA Cleared product.
Must have missed February 2021, BIEL hit.0088 on 472 million shares traded
<<<<<<<<<<<<< "a SP of 1 cent?" >>>>>>>>>>>>>
Date Close Change Change (%) Open High........ Low ......... Volume
Feb 26 2021 0.00477 -0.00023 -4.6% 0.0054 0.0057 0.0045 105,974,674
Feb 25 2021 0.005 -0.0007 -12.28% 0.0055 0.006 0.0035 470,036,436
Feb 24 2021 0.0057 -0.00055 -8.8% 0.0062 0.0065 0.0054 156,794,128 on
Feb 23 2021 0.00625 -0.00095 -13.19% 0.0074 0.0074 0.0053 139,049,732
Feb 22 2021 0.0072 0.0005 7.46% 0.0069 0.008 0.0067 128,354,684
Feb 19 2021 0.0067 -0.0001 -1.47% 0.007 0.0071 0.0064 60,896,342
Feb 18 2021 0.0068 -0.00043 -5.91% 0.0076 0.0078 0.006 173,218,802
Feb 17 2021 0.007227 0.00028 3.99% 0.008 0.008 0.0069 159,777,052
Feb 16 2021 0.00695 0.0007 11.2% 0.008 0.008 0.0065 126,909,624
Feb 12 2021 0.00625 -0.00115 -15.54% 0.0075 0.0088 0.0048 472,346,770
Feb 11 2021 0.0074 0.00254 52.11% 0.0053 0.0075 0.0046 465,619,397
Feb 10 2021 0.004865 0.00032 6.92% 0.0048 0.006 0.0045 194,023,167
Feb 09 2021 0.00455 0.00055 13.75% 0.0045 0.0048 0.0044 161,720,016
Feb 08 2021 0.004 0.0004 11.11% 0.0036 0.004 0.0036 187,013,985
"In exchange for the extensions"
So if the lender Converts after 2 years the Issuance Conversion Rate remains in place.
This makes perfect sense as lenders take a risk in committing their money for 2 years and in the Penny Stock market it is a larger risk given the high percentage of Penny Stock companies that fail. If they are going to leave their money at risk for an additional 2 years there should be an adjustment.
I actually think the Conversion Rate being based on the Conversion Date is an excellent deal for a Profitable BIEL.
If I enter into a Conversion Loan today with BIEL at .0005 my Conversion Rate would be .00025. If BIEL is trading at .005 in two years on my Conversion Date I receive an enormous profit.
The lenders who Extended their loans and went to the 'Conversion Rate at Conversion Date' are capped at a 50% Conversion bonus..
This has major implications for a Profitable BIEL. At a .00025 Conversion Rate it would take north of 40 billion shares to pay off BIEL's Convertible Loans. At a SP of 1 cent and a Conversion Rate, .005, established on the Conversion Date it would only take 2 billion shares to pay off the same debt.
And your proof of that Opinion.... because until documentation is provided it is just an Opinion
The only statement found in the financials,
"The conversion prices on the convertible notes payable have generally been 50% or less of the pink sheet closing price of the common stock on the date the notes or advances are issued"
People keep bringing up 50% discount at conversion
When I read the financials this is what BIEL states about convertible loans;
"The conversion prices on the convertible notes payable have generally been 50% or less of the pink sheet closing price of the common stock on the date the notes or advances are issued to reflect the restricted nature of the stock into which the notes could be converted and the Board of Directors’ belief that the closing stock price is not reflective of the fair market value of the common stock due to the price volatility, and lack of an active market for trading shares resulting in limited trading volume of share transactions. The Board of Directors is active in negotiating conversion prices for each issuance and takes into consideration all information in establishing the issuance date fair market value."
So, 50% or less at the Issuance Date SP not the Conversion Date, with BIEL willing to negotiate if the Conversion Date SP is significantly lower than the Issuance Date SP.
From the BIEL Q3 2022 Disclosure Statement, this policy demonstrated;
"During the second quarter of 2018, the Company entered into a convertible note agreement with Abhinav Humar, receiving financing of $160,000, with an interest rate of 8% per annum and convertible at a rate of $.0013 per share. The balance on this loan was $224,450 as of September 30, 2022."
This loan was Issued on 5/18/2018. BIEL's SP ranged from a high of .0031 to a low of .0021 during this week.
Reading Material for you re dilution concerns:
Sunday, October 23, 2022 11:29:10 AM
Post# 301191
Several Very Large Holes in that Opinion
Convertible Note Holders have to Convert their Loans to Shares before they can Sell
BIEL has only 295 million shares available to pay back Convertible Note Holders with before they hit their 'Authorized Share' limit
All of BIEL's current Convertible Loans are with 'Friendly Lenders' who have rolled over their Loans in the past, IBEX, St John's, Dr Staelin, T. Kim, Jarman
Since Dr Staelin rejoined BIEL as COB in 2020 all of his many Loans to BIEL have been Principle & Interest only, No Conversion option
St John's also switched to Principle & Interest Loans in January 2022
Tuesday, November 15, 2022 3:43:17 PM
Post# 302216
BIEL showed 24.705 billion shares outstanding in the Q1 2022 Financials
BIEL showed 24.705 billion shares outstanding in the Q3 2022 Financials.
That is zero dilution in Q2 and again in Q3 2022.
St John's has made $91k in Interest Only Loans to BIEL in 2022.
Dr. Staelin has made $535k in Interest Only Loans to BIEL since he returned to the COB position in 2020.
Erin Sanders made a $25k Interest Only Loan to BIEL in Q3 2022.
IBEX and St John's have saved BIEL $2.5 million by foregoing the interest on their loans over the last several years.
Everyone at BIEL is serious about controlling dilution and bringing BIEL to profitability.
Saturday, November 19, 2022 10:35:50 AM
Post# 302488
The Disclosure Statements also show that Dr Staelin's last conversion was over 3 years ago in September 2019
He has been Rolling Over his convertible loans for another 2 years since he took over the COB position in 2020.
He has made over $500k in new loans since 2020 and they are all Interest Only loans, no conversion option.
Disclosure shows that the last conversion by BIEL's CEO was in March of 2019. She has Rolled Over dozens of convertible loans for another 2 years saving BIEL billions of shares in dilution.
BIEL's CEO has also foregone millions of dollars of interest, which means canceling it not delaying it, to help BIEL reach profitability sooner.
Only 5 million shares remain on the 5 Ask
Bid size = 110 million shares
Buys = 23 million shares
Sells = 882k shares
2:38 Update, 5s gone
Adcock Ingram is Serious about Relieving Pain
Pain is the oldest medical problem and the most common reason we seek medical care. It is often classified as acute or chronic depending on how long the pain is present. As pain is a subjective experience, doctors assess pain severity on a rating scale according to personal reports by patients. The World Health Organization (WHO) recommends clinicians treat pain according to a ‘Pain Ladder’, which allocates medication classes according to the severity of the pain – as you go up the ‘pain severity ladder’, different classes of medication are added for pain relief.
Our range of products can be used for acute pain relief or for long-term chronic treatment of various painful conditions including but not limited to: headache with or without tension, low back pain, muscle spasms, inflammatory conditions, sports injuries, dental pain, cancer pain and post-operative pain.
Speak to you pharmacists about the Adcock Ingram's range of products available over the counter. For more severe pain, consult your Doctor for Adcock Ingram's Prescription Pain medication.
BIEL started today with 27 million shares on the 5 Ask
That has now been whittled down to 13.9 million shares.
Buys = 14 million shares
Sells = 842k shares
Thanks JGD and Hawk, We missed a Merry Christmas but will have a Happy New Year
10 Pallets to Adcock Ingram
Go BIEL !!!
Go Adcock Ingram !!!
https://twitter.com/bielcorp
I don't recall anyone at BIEL ever saying that an 11 digit OS count did not need to be addressed
What BIEL has said , both AW and KW, was that once the company was profitable the share count would be addressed. This would be addressing the OS from a position of strength, as a profitable enterprise, verses as a struggling company that could be subjected to Market manipulation. See ENDV as an example of where their 2 Reverse Splits got them and their investors, 1 for 100 and 1 for 1,000 ..
Nope, Scam companies RS every few years to hide their losses
BIEL = zero RS after 20 years.
Scam companies don't have a dozen UCSD Researchers, Surgeons and Anesthesiologists calling for larger Studies on their products.
Scam companies don't have their CEOs foregoing millions of dollars in interest.
Scam companies don't have their CEOs deferring their salary.
Scam biotech companies don't hold 5 FDA 510k Indications for medical conditions.
Scam companies don't have companies the size of STADA and Adcock Ingram signing contracts with them.
No one is happy with the .0004 SP but it has happened several times in BIEL's history as shareholders grow tired of waiting for a material event.
The important thing to remember is that BIEL has always bounced back with significant news and Synergy is by far the Biggest Deal in BIEL's history.
IMO, we see the largest run BIEL has ever had once the Synergy PR is released.
Good Grief, 510k #K192234, 1/31/2020, OTC Musculoskeletal Pain
<<<<<<< Keith said there was a "new 510k" in 2020? Really? For what indication? >>>>>>>
Let me guess, that "Market Research" was conducted by Fantasy 'Sales Track'
Dr Ilfeld knows the process to get large Studies funded
He is highly respected in the research community so when he writes a paper, even if it is just a 'Proof of Concept', Doctors, Researchers and the DOD take notice.
Dr Ilfeld Research Activities And Funding
Eliminating Post-Mastectomy Pain and Opioids with Percutaneous Cryoneurolysis: A Single-Administration, Non-Opioid, Non-Addictive, Multiple-Month Analgesic
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP)W81XWH-21-PRMRP-CTA (PR212158)Sep 30, 2022 - Sep 29, 2026
Role: Principal Investigator
Description: $5,290,392
Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Non-Pharmacologic Alternative for the Treatment of Postoperative Pain
Department of Defense Congressionally Directed Medical Research Programs, NIH-DoD-VA Pain Management Collaboratory—Pragmatic Clinical Trials Demonstration Projects (UG3/UH3)W81XWH-18-2-0009 (NH170005)May 1, 2018 - Apr 30, 2024
Role: Principal Investigator
Description: $6,971,337
Improving Postamputation Functioning by Decreasing Phantom Limb Pain and Opioid Use With Perioperative Continuous Peripheral Nerve Blocks: A Multicenter RCT
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Orthopaedic Research Program (PRORP)W81XWH-17-1-0671 (OR160012)Sep 30, 2017 - Sep 29, 2023
Role: Principal Investigator
Description: $2,847,215
Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Definitive Human Subjects Clinical Trial
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP)W81XWH-17-2-0051 (PR160263)Sep 30, 2017 - Sep 29, 2023
Role: Principal Investigator
Description: $3,950,572
Treating Intractable Post-Amputation Phantom Limb Pain with Ambulatory Continuous Peripheral Nerve Blocks
Department of Defense Congressionally Directed Medical Research Programs Defense Medical Research and Development ProgramW81XWH-13-2-009Jan 25, 2012 - Dec 24, 2020
Role: Principal Investigator
Description: $2,617,000
For those who need reminding of what a scam company looks like....
Our good friends at ENDV are happy to comply.
ENDV purchased a concrete company, with shares as they have no cash, several months ago because concrete and prescription PEMF devices have a lot in common, right.
ENDV just announced that they are splitting off the Sofpulse medical device business into a new company, 'NewCo'. ENDV which currently has a Market Cap of $2.7 million stated the following,
"Management expects on completion of the spinoff, NewCo will have a pre-money valuation of over $50 million. NewCo’s management believes it can take the company to over $100 million in sales by 2024."
This from a company who has never sold more than a few hundred devices per Quarter.
Meanwhile BIEL is actually selling PEMF medical devices, recently signing the largest contract in BIEL's history with Synergy Corp.
https://www.mpo-mag.com/contents/view_breaking-news/2022-12-19/endonovo-to-spin-off-medical-ip-and-assets/24664
Well said Miami
Marketing to a country the size of the US would require a massive Advertising and Distribution budget that BIEL does not have. BIEL got a taste of volume retail selling costs when they were in a couple thousand UK pharmacies. Highest Sales Revenue in BIEL's history but also the highest Net Losses.
Synergy is the Largest Contract in BIEL's history, 25 countries, 975,000 devices over 18 months. It is still happening.
How about some details on that "here it is"
2,000 shares @ .0004
515,000 shares @ .00045
17 million shares @ .0005